Cargando…
Oral melphalan as a treatment for platinum-resistant ovarian cancer
A large number of drugs have been used to treat recurrent ovarian cancer, yet there are few data that guide the physician's choice. Typically, the decision to re-treat with platinum-based therapy depends on the progression-free interval. However, the optimum agent for the treatment of platinum-...
Autores principales: | Hasan, J, Jayson, G C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741128/ https://www.ncbi.nlm.nih.gov/pubmed/12799622 http://dx.doi.org/10.1038/sj.bjc.6601044 |
Ejemplares similares
-
Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002) -
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
por: van der Burg, M E L, et al.
Publicado: (2002) -
Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993) -
The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
por: Mistry, P., et al.
Publicado: (1991) -
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer
por: Chen, Siqi, et al.
Publicado: (2022)